In humans, Tet2 mutations occur in ~10–30% of myeloid cancers, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and myeloproliferative neoplasm (MPN)19. This evidence concerns the gene TET2 and myeloproliferative disorder.